--- title: CDMO Daily News — October 7, 2026 slug: daily-news-2026-10-07-cdmo site: cdmo post_kind: news byline: BioBM description: October 7 CDMO daily: Curia Invests $28M to Expand Sterile API Manufacturing in Spain; Catalent Launches 10-Month Gene-to-Drug Substance Program for Complex… canonical_url: https://www.cdmo.directory/posts/daily-news-2026-10-07-cdmo published_at: 2026-10-07T00:00:09.686Z last_updated: 2026-10-07T00:01:12.800Z --- ### [Curia](/companies/curiaglobal) Invests $28M to Expand Sterile API Manufacturing in Spain - [Curia](/companies/curiaglobal) is investing $28 million to expand sterile API manufacturing at its Valladolid, Spain facility, with completion targeted for Q4 2028. - The expansion will support both steroid and non-steroid injectable suspensions and complex sterile formulations, with manufacturing flexibility from grams to metric tons using closed-system barrier isolators. - The project builds on Curia's May 2026 completion of a $4 million aseptic suite upgrade at the same site, strengthening integrated R&D, analytical, and manufacturing services. **Operational Impact** [Curia](/companies/curiaglobal)'s Valladolid sterile API expansion adds European GMP capacity for injectable suspensions and complex sterile formulations, offering CDMO buyers variable batch-size manufacturing and reduced contamination risk through barrier-isolator technology by late 2028. *Source: [PharmaSource RSS](https://pharmasource.global/content/news/cdmo-news/curia-invests-to-expand-sterile-api-manufacturing-in-spain)* --- ### [Catalent](/companies/catalent) Launches 10-Month Gene-to-Drug Substance Program for Complex Biologics - [Catalent](/companies/catalent) introduced an accelerated U.S. program delivering bispecifics and multispecifics from gene sequence to drug substance in 10 months, complementing its existing 8-month mAb timeline. - The offering integrates GPEx® Lightning cell line development with development and manufacturing workflows, with three customer-facing milestones: master cell bank conditional release (month 7), bulk drug substance shipment (month 9), and lot release (month 10). - The program bridges early development to clinical supply and positions Catalent's integrated drug substance and drug product capabilities for fill-finish readiness. **Operational Impact** [Catalent](/companies/catalent)'s 10-month complex biologics program with defined milestones (month 7 cell bank, month 9 bulk shipment, month 10 release) offers CDMO buyers a predictable compressed timeline for next-generation molecules entering clinical development. *Source: [PharmaSource RSS](https://pharmasource.global/content/news/cdmo-news/catalent-launches-10-month-gene-to-drug-substance-program-for-complex-biologics)* --- ### [Flamma](/companies/flammagroup) Acquires Lundbeck's Padova API Site, Adding 220 m³ Italian Capacity - [Flamma](/companies/flammagroup) will acquire Lundbeck Pharmaceuticals Italy's Padova facility, adding 220 m³ of cGMP API manufacturing capacity effective January 1, 2027. - The site brings Flamma's total Italian capacity to ~1,100 m³ across four Northern Italy locations, with capabilities in hydrogenation, micronization, high-pressure and hazardous chemistry. **Operational Impact** [Flamma](/companies/flammagroup)'s four-site Northern Italy cluster and expanded 1,100 m³ capacity strengthen its small-molecule API and peptide supply capability for commercial-stage clients seeking European manufacturing proximity. *Source: [PharmaSource RSS](https://pharmasource.global/content/news/cdmo-news/flamma-acquires-lundbeck-api-site-in-italy)* --- ### [Genezen](/companies/genezen) to Manufacture AAV8 Gene Therapy for InterAct Therapeutics Breast Cancer Program - [Genezen](/companies/genezen) will provide AAV process development, scale-up, and GMP manufacturing for InterAct Therapeutics' IAT-S2, an AAV8-based gene therapy targeting breast cancer liver metastases. - Manufacturing support covers toxicology studies and clinical material production for a planned Phase 1 trial following positive FDA INTERACT feedback. **Operational Impact** [Genezen](/companies/genezen)'s Indianapolis GMP facility adds AAV8 manufacturing capacity for a Phase 1-stage gene therapy program, demonstrating continued demand for specialized AAV CDMO services in oncology. *Source: [PharmaSource RSS](https://pharmasource.global/content/news/cdmo-news/genezen-partners-with-interact-therapeutics-on-aav8-cancer-gene-therapy)* ## References 1. [PharmaSource RSS — Curia Invests $28M to Expand Sterile API Manufacturing in Spain](https://pharmasource.global/content/news/cdmo-news/curia-invests-to-expand-sterile-api-manufacturing-in-spain) 2. [PharmaSource RSS — Catalent Launches 10-Month Gene-to-Drug Substance Program for Complex Biologics](https://pharmasource.global/content/news/cdmo-news/catalent-launches-10-month-gene-to-drug-substance-program-for-complex-biologics) 3. [PharmaSource RSS — Flamma Acquires Lundbeck's Padova API Site, Adding 220 m³ Italian Capacity](https://pharmasource.global/content/news/cdmo-news/flamma-acquires-lundbeck-api-site-in-italy) 4. [PharmaSource RSS — Genezen to Manufacture AAV8 Gene Therapy for InterAct Therapeutics Breast Cancer Program](https://pharmasource.global/content/news/cdmo-news/genezen-partners-with-interact-therapeutics-on-aav8-cancer-gene-therapy) Source: https://www.cdmo.directory/posts/daily-news-2026-10-07-cdmo